Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

An2 Therapeutics Inc (ANTX)

An2 Therapeutics Inc (ANTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 75,766
  • Shares Outstanding, K 29,829
  • Annual Sales, $ 0 K
  • Annual Income, $ -64,730 K
  • 60-Month Beta -0.12
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.69
Trade ANTX with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.63
  • Number of Estimates 2
  • High Estimate -0.60
  • Low Estimate -0.65
  • Prior Year -0.81
  • Growth Rate Est. (year over year) +22.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.91 +35.08%
on 06/13/24
2.94 -12.24%
on 07/08/24
+0.65 (+33.68%)
since 06/12/24
3-Month
1.91 +35.08%
on 06/13/24
2.94 -12.24%
on 07/08/24
-0.16 (-5.84%)
since 04/12/24
52-Week
1.91 +35.08%
on 06/13/24
22.22 -88.39%
on 01/10/24
-5.44 (-67.83%)
since 07/12/23

Most Recent Stories

More News
The Five Biotech Stocks Every Investor Should Know About

Avalon GloboCare Corp., (NASDAQ: ALBT) a developer of innovative precision diagnostics and provider of clinical laboratory services just announced that the United States Patent and Trademark Office (USPTO)...

ALBT : 0.4830 (+1.53%)
INSM : 76.71 (-0.42%)
VIR : 9.37 (+2.29%)
CODX : 1.3500 (+3.85%)
ANTX : 2.58 (+1.57%)
A Potentially Revolutionary Tuberculosis Test Can Produce Results in 24 Hours

With a rising prevalence of chronic diseases, we’re starting to see higher demand for clinical lab services. That being said, it’s no surprise that, according to Market.Us, the global market for clinical...

INSM : 76.71 (-0.42%)
VIR : 9.37 (+2.29%)
CODX : 1.3500 (+3.85%)
ANTX : 2.58 (+1.57%)
ALBT : 0.4830 (+1.53%)
Brii Biosciences Provides Latest Clinical Development and Corporate Updates

Company extends BRII-179 license to global rights and introduces preventive vaccine, PreHevbri® in Greater China and Asia Pacific markets New data from...

VIR : 9.37 (+2.29%)
VBIV : 0.7870 (+0.96%)
ANTX : 2.58 (+1.57%)
AN2 Therapeutics to Present at JMP Securities Life Sciences Conference

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced...

ANTX : 2.58 (+1.57%)
AN2 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported...

ANTX : 2.58 (+1.57%)
Brii Biosciences Provides Corporate Update and Reports Full-Year 2022 Financial Results

/PRNewswire/ -- Brii Biosciences Limited ("Brii Bio," "we," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve...

VIR : 9.37 (+2.29%)
VBIV : 0.7870 (+0.96%)
ANTX : 2.58 (+1.57%)
AN2 Therapeutics to Participate in Upcoming Investor Conferences

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced...

ANTX : 2.58 (+1.57%)
AN2 Therapeutics to Present at SVB Securities Global Biopharma Conference

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced...

ANTX : 2.58 (+1.57%)
AN2 Therapeutics Initiates Pivotal Phase 2/3 Trial Evaluating Epetraborole for Treatment-Refractory MAC Lung Disease

AN2 is developing epetraborole as a once-daily, orally administered treatment with a novel mechanism of action for patients with NTM lung disease, with an...

ANTX : 2.58 (+1.57%)
AN2 Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates

On Track for Several Milestones in 2022, and Supported by Strong Balance Sheet from Upsized Initial Public Offering Continued Progress Advancing...

ANTX : 2.58 (+1.57%)

Business Summary

AN2 Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on developing treatments for rare, chronic and serious infectious diseases with high unmet needs. AN2 Therapeutics Inc. is based in MENLO PARK, Calif.

See More

Key Turning Points

3rd Resistance Point 2.71
2nd Resistance Point 2.65
1st Resistance Point 2.62
Last Price 2.58
1st Support Level 2.53
2nd Support Level 2.47
3rd Support Level 2.44

See More

52-Week High 22.22
Fibonacci 61.8% 14.46
Fibonacci 50% 12.06
Fibonacci 38.2% 9.67
Last Price 2.58
52-Week Low 1.91

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar